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Introduction: Primary open-angle glaucoma (POAG) is one of the leading causes of   blindness. 
Activation of optic nerve head astrocytes (ONHA) and loss of trabecular meshwork cells (TMC) 
are pathognomonic for this neurodegenerative disease. Oxidative stress and elevated levels of 
transforming growth factor beta (TGFβ) play an important role in the pathogenesis of POAG. 
This study investigates the possible antiapoptotic and cytoprotective effects of minocycline on 
TMC and ONHA under oxidative stress and increased TGFβ levels.
Methods: TMC and ONHA were treated with minocycline 1–150 µM. Possible toxic effects 
and IC50 were evaluated after 48 hours. Cell proliferation and viability were examined in order 
to assess the protective effects of minocycline on TMC and ONHA. Expression of Bcl-2, XIAP, 
and survivin, as well as their mRNA expression, were assessed by real time polymerase chain 
reaction (RT-PCR) and Western Blot analysis 48 hours after treatment with minocycline alone 
and additional incubation with TGFβ-2 or oxidative stress.
Results: Minocycline 1–75 µM showed no toxic effects on TMC and ONHA. Under condi-
tions of oxidative stress, both TMC and ONHA showed an increase in viability and an ability 
to proliferate when treated with minocycline 20–40 µM. RT-PCR and Western blotting yielded 
an overexpression of Bcl-2, XIAP, and survivin when TMC or ONHA were treated with 
minocycline 20–40 µM under conditions of oxidative stress and when additionally incubated 
with TGFβ-2.
Conclusion: Minocycline up to 75 µM does not have toxic effects on TMC and ONHA. Treat-
ment with minocycline 20–40 µM led to increased viability and proliferation under oxidative 
stress and TGFβ-2, as well as overexpression of Bcl-2, XIAP, and survivin. This protective path-
way may help to prevent apoptotic cell death of TMC and ONHA and therefore be a promising 
approach to avoidance of progression of glaucomatous degeneration.
Keywords: glaucoma, apoptosis, minocycline, trabecular meshwork, optic nerve head 
astrocytes
Introduction
Glaucoma is a chronic optic neuropathy characterized by retinal ganglion cell (RGC) 
loss, excavation of the optic nerve, and concomitant visual field defects.1 It is the second 
leading cause of blindness, and almost 75 million people are affected worldwide.2–4 
Elevated intraocular pressure (IOP) is the main risk factor for the development5 and 
progression6 of glaucomatous damage, and most cases of glaucoma are associated with 
elevated IOP.7,8 Elevated IOP results from increased aqueous outflow resistance, and 
is due to several morphologic changes in the trabecular meshwork (TM). including Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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trabecular cell loss.6,9,10   Additional factors, such as nutritional 
status11 and retinal ischemia,12,13 have been implicated as 
pathognomonic, and there is growing evidence that oxidative 
stress14–16 and elevated levels of transforming growth factor 
beta (TGFβ)17,18 play a crucial role in the pathogenesis of 
glaucoma. It has also been shown in several animal models 
and in human glaucoma that both RGC and TM cells (TMC) 
die as a result of apoptosis.16,19–24
Minocycline is a semisynthetic, second-generation 
tetracycline that crosses the blood–brain barrier effec-
tively,25 penetrates well into the eye,26 and has had proven 
antimicrobial and anti-inflammatory efficacy for many 
years.27,28 In ophthalmology, minocycline has been sug-
gested as a treatment for several palpebral disorders 
and age-related macular degeneration, due to its anti-
inflammatory activities.29 In addition to its antibiotic and 
anti-inflammatory activities, it has shown neuroprotective 
properties in experimental models of several neurodegen-
erative diseases, including multiple sclerosis, Parkinson’s 
disease, Huntington’s chorea, amyotropic lateral sclerosis, 
ischemic stroke, traumatic brain injury, and optic nerve 
transection.30–35
The neuroprotective effects of minocycline are con-
sidered to be anti-inflammatory and antiapoptotic. Recent 
reports have demonstrated the antioxidant properties and 
influence of minocycline on caspases and nitric oxide syn-
thase activity.36 Minocycline has an inhibiting effect on the 
release of apoptotic proteins, including cytochrome c and 
Smac/DIABLO, and induces antiapoptotic proteins, such as 
Bcl-2 or XIAP.30,37,38 These effects have been demonstrated 
mainly for cells derived from the nervous system but also 
for non-neuronal cells, such as kidney epithelial cells.38 
A rodent study evaluating the effects of minocycline on 
RGC in experimental glaucoma revealed enhanced survival 
of RGC because of delayed apoptosis39 but, so far, little 
is known about the possible protective and antiapoptotic 
effects of minocycline on the TM and neuroretinal cells of 
the human eye.
In this study, we investigated the effects of minocycline 
on primary human optic nerve head astrocytes (ONHA) and 
primary human TMC with regard to viability and cell death, 
and we evaluated whether toxic effects occur and, if so, at 
which concentrations of minocycline. In order to investi-
gate the possible antiapoptotic effects of minocycline, the 
expression of Bcl-2, XIAP, survivin, as well as their mRNA 
expression, were determined when cells were treated with 
minocycline, under oxidative stress or elevated levels of 
TGFβ, to simulate glaucomatous conditions.
Methods
human optic nerve head astrocytes
Primary cell cultures of human lamina cribrosa astrocytes 
were obtained from the Ludwig-Maximilian-University eye 
bank in Munich, Germany. Monolayer cultures were estab-
lished from eyes of four human donors (aged 35, 53, 58, and 
72 years, obtained 3–10 hours post mortem) without any 
history of eye diseases. The eyes were prepared and grown 
as previously described.40–42
human trabecular meshwork cells
Cultures of human TMC were established from the same 
donors as for the ONHA according to protocols published 
previously.40,43,44 TMC of passages 3–6 were seeded in 
6-well plates and grown to a confluent monolayer. After 
seven days’ confluence, the wells were treated with mino-
cycline as described below. Primary TMC and ONHA of 
passages 3–6 were used in the experiments. All procedures 
for gathering human tissue were undertaken with appropri-
ate consent, complied with the Declaration of Helsinki, and 
were approved by the local ethics committee.
Cell culture treatment
For the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide] assay and viability testing, TMC   (passages 3–6) 
and ONHA (passages 3–6) were seeded in 6-well plates and 
exposed to minocycline concentrations of 1, 5, 7.5, 10, 15, 20, 
40, 50, 75, 100, and 150 µM. To investigate the effects of mino-
cycline on TMC and ONHA and on RNA and protein levels, 
minocycline concentrations of 20 and 40 µM were tested.
Before treatment, TMC and ONHA were kept for 24 hours 
in serum-free conditions. The cells were washed with phosphate-
buffered saline (PBS) and incubated for 48 hours with minocy-
cline concentrations soluted in DMEM/F12 medium for both 
TMC and ONHA cell lines. The tested substance concentrations 
were then removed by carefully rinsing the cells with serum-free 
medium three times. Thereafter, the cell proliferation assay, RNA 
isolation, and protein extraction was performed.
For testing the effects of minocycline under conditions of 
oxidative stress, cells were treated for 48 hours with the differ-
ent minocycline concentrations and addition of 600 µM H2O2 
for the last four hours. Thereafter the serum-free medium 
containing H2O2 and minocycline was removed by carefully 
rinsing the cells with serum-free medium three times. After 
another four hours of incubation with serum-free medium, 
cell proliferation assay, RNA isolation, and protein   extraction 
was performed.Clinical Ophthalmology 2010:4
Table 1 Primer used for reverse transcription polymerase chain reaction
Target Length Position AT(°C) %GC Sequence
Bcl-2 19 3465–3483 60 58 AgAggTCACgggggCTAAT
20 3505–3524 60 50 CCAggTAACAAAACCCCACA
XiAP 25 46–870 60 36 TTTTQQQACATggATATACTCAQTT
25 910–934 59 40 A gCACTTTACTTTATCACCTTCACC
survivin 20 284–303 59 50 gCCCAgTgTTTCTTCTgCTT
20 350–369 60 45 CCggACgAATgCTTTTTATg
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To test the effects of minocycline under treatment with 
TGFβ-2, the cells were first treated for 24 hours with the vari-
ous concentrations of minocycline followed by addition of 
1 ng/mL TGFβ-2. After another 24 hours of incubation with 
minocycline and TGFβ-2, RNA isolation and protein extrac-
tion was performed.
MTT assay
The MTT assay was used to determine the cell survival rate. 
This assay, as performed in our study, is a well established 
test for cell viability. It was performed as described in the 
literature by Mosmann,45 with some modifications. The 
medium was removed, cells were washed with PBS, and 
1000 µL/well MTT solution (1.5 mL MTT stock, 2 mg/mL 
in PBS, plus 28.5 mL DMEM) was added. TMC and ONHA 
were incubated at 37°C for one hour. The formazan crystals 
that formed were dissolved by the addition of dimethyl-
sulfoxide (1000 µL/well). Absorption was measured by a 
scanning multiwell spectrophotometer at 550 nm (Molecular 
Probes, Garching, Germany). Results were expressed as the 
mean percentage of control proliferation. Experiments were 
performed in triplicate and repeated three times. TMC and 
ONHA of the same passage incubated with balanced saline 
without the addition of dyes served as the control.
Viability assay
Confluent TMC and ONHA were prepared and treated as 
described above. Cell viability was quantified based on a two-
color fluorescence assay in which the nuclei of unviable cells 
appear red because of staining by the membrane-impermeable 
dye, propidium iodide (Sigma-Aldrich, Steinheim, Germany), 
while the nuclei of all cells were stained with the membrane-
permeable dye Hoechst 33342 (Intergen,   Purchase, NY). 
Confluent cultures of TMC or ONHA growing on coverslips 
in 24-well tissue culture plates were exposed to the various 
concentrations of minocycline as described above for the 
MTT assay. To evaluate cell viability, the cells were washed in 
PBS and incubated with 2.0 µg/mL propidium iodide and 1.0 
µg/mL Hoechst 33342 for 20 minutes at 37°C. Subsequently, 
the cells were   analyzed with an epifluorescence microscope 
(Aristoplan, Leitz, Wetzlar,   Germany). The labeled nuclei 
were then counted in fluorescence   photomicrographs, and 
dead cells were expressed as a percentage of the total nuclei 
in the field. The data are based on counts from three experi-
ments performed in duplicate wells, with 3–5 documented 
  representative fields per well. TMC and ONHA of the same 
passage incubated with   serum-free medium served as the 
control.
rnA isolation and real-time polymerase 
chain reaction
Total RNA was isolated from 10 cm Petri dishes by the 
guanidium thiocyanate-phenol-chloroform extraction method. 
Structural integrity of the RNA samples was confirmed by 
electrophoresis in 1% Tris-acetate-ethylenediamine tetraa-
cetic acid agarose gels. The yield and purity were determined 
photometrically (BioPhotometer, Eppendorf, Germany). 
Real-time polymerase chain reaction   (RT-PCR) enables 
quantitative detection of small amounts of mRNA. After 
the usual isolation of mRNA, this mRNA was   transferred to 
cDNA via reverse transcriptase. This cDNA was then used for 
the specific PCR. Quantitation of Bcl-2, survivin, and XIAP 
mRNA was performed with specific primers (see Table) with 
a   LightCycler Instrument (LightCycler System, Roche Diag-
nostics,   Mannheim, Germany). Primers and probes were found 
with the program ProbeFinder version 2.04. All primers and 
probes were designed to cross intron/exon boundaries, in order 
to avoid amplification of genomic DNA. All PCR products 
were sequenced to ensure product validity. Each 14 µL reaction 
volume contained 1 × FastStart DNA Master Hybridization 
Probes Mix (Roche Diagnostics), 4 mM MgCl2, 0.5 mM of 
each primer, 0.2 mM TaqMan probe, and 2 µL cDNA.
The amplification signals were detected in real time, which 
enabled accurate quantification of the amounts of the initial 
RNA template, because the system can select signals easily 
during the exponential amplification phase of PCR. The cDNA 
of cells either treated with minocycline alone (20 µM and 40 
µM) or additionally treated with TGFβ-2 (1 ng/mL) or 600 Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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µM H2O2 was amplified with specific primers for 40 cycles. 
Two oligonucleotides with   differently-labeled fluorophores 
were hybridized to the amplified fragment during the anneal-
ing phase. When the two probes came into close proximity, 
fluorescence resonance energy transfer developed between the 
two fluorophores. The   emitted   fluorescence was then measured 
by the LightCycler   instrument. Hybridization probes were 
displaced during the extension step. Depending on the initial 
concentration of target genes, the signal intensity increased 
in different cycles, and these cycles were used as the crossing 
point. The standard curve was made with three different probes 
of untreated TMC or ONHA. To normalize for differences in 
the amount of total RNA added to each reaction, 18S rRNA 
was simultaneously processed in the same sample as an inter-
nal control. The level of Bcl-2, survivin, and XIAP mRNA 
was determined as the relative ratio, which was calculated 
by dividing the level of Bcl-2, survivin, and XIAP mRNA 
by the level of the 18S rRNA housekeeping gene in the same 
samples. Ratios were expressed in a decimal format. All 
experiments were performed at least in triplicate and repeated 
three times.
Protein extraction and western  
blot analysis
TMC and ONHA grown on 35 mm tissue culture dishes 
were washed twice with ice-cold PBS, collected, and lysed 
in radioimmunoprecipitation assay cell lysis buffer. After 
centrifugation for 30 minutes at 19,000 × g in a microfuge 
(5810R, Eppendorf, Hamburg, Germany) in cold conditions, 
the supernatant was transferred to fresh tubes and stored at 
-70°C for future use. The protein content was measured by 
the bicinchoninic acid protein assay (Pierce, Rockford, IL). 
Denatured proteins (1e2 mg) were separated by electropho-
resis under reducing conditions using a 5% sodium dodecyl 
sulfate-polyacrylamide stacking gel and a 12% sodium dode-
cyl sulfate-polyacrylamide separating gel, transferred with 
semidry blotting onto a polyvinyl difluoride membrane and 
probed with a mouse anti-Bcl-2 antibody, a mouse anti-sur-
vivin antibody, or a mouse anti-XIAP antibody, as described 
previously.46 Chemiluminescence was detected with an imager 
(LAS-1000, RayTest) and generated light units. Exposure 
times were in the range 1–10 minutes. Quantification was 
performed on a computer (AIDA software, RayTest). All 
experiments were performed at least in triplicate and repeated 
three times in ONHA and TMC cultures from three donors. 
An even protein load in each lane was confirmed by staining 
of the polyvinyl difluoride membranes with   Coomassie Bril-
liant Blue after the blotting procedure.
statistics
All data were entered in an MS-Excel 2000 spreadsheet 
(Microsoft Corporation, Redmond, WA) and analyzed 
using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL). 
All   statistical tests were considered significant at P , 0.05. 
In detail, the statistical comparison between the different 
concentrations of minocycline (each measured in tripli-
cate and performed three times) was performed using the 
  Mann-Whitney test. For the MTT assay, quantitative results 
are presented as mean (± standard deviation, SD) units of 
absorbance. Ten individual samples per group were measured 
in triplicate and performed three times, and comparisons 
performed applying the Mann-Whitney test. For RT-PCR, the 
results are presented as mean ratios (± SD) of the investigated 
mRNA and 18S rRNA. Again, Mann-Whitney testing was 
applied, and all experiments were performed in triplicate and 
repeated three times. Western Blot analysis was performed 
analogous, experiments were performed at least in triplicate 
in ONHA and TMC cultures from three donors.
Results
Concentrations of minocycline in primary 
human TMC and OnhA
Minocycline concentrations of 1, 5, 7.5, 10, 15, 20, 40, 50, 
75, 100, and 150 µM were chosen to investigate the possible 
toxic effects of minocycline on TMC and ONHA. With 
phase-contrast microscopy, no gross abnormalities could 
be detected in primary TMC and ONHA for minocycline at 
concentrations up to 75 µM. The numbers of cells counted in 
phase-contrast microscopy were comparable with the results 
of the MTT test (data not shown).
When TMC and ONHA were additionally treated with 
600 µM H2O2, those cells treated with 20 µM and 40 µM 
minocycline did not show any signs of toxicity, cellular 
death, or other abnormalities. The control cells treated 
with 600 µM H2O2 alone showed pronounced morphologic 
signs of toxicity, including abnormal shape and appearance, 
  cellular lysis, and destruction (Figure 1). When ONHA and 
TMC were treated with 20 µM and 40 µM minocycline and 
additionally with TGFβ-2, the cells did not show any signs 
of toxicity, cellular death, or other abnormalities (data not 
shown). The concentration of minocycline that inhibited 
control cell growth by 50% (IC50) was determined from the 
dose-response curves (data not shown). For a 24-hour appli-
cation, this concentration was approximately 75 µM (95% 
confidence interval [CI]: 65.5–84.5) for primary TMC and 
100 µM for ONHA (95% CI: 88.8–111.2).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
595
Cytoprotective effect of minocycline
MTT assay
Minocycline showed no significant toxic effects in the two 
investigated cell cultures (48 hours exposure) at concentra-
tions between 1 µM and , 50 µM (Figures 2 and 3). All 
experiments were performed at least in triplicate and repeated 
three times. No significant decrease was detected in cellular 
viability for either primary TMC or ONHA, compared with 
the controls at concentrations ,50 µM. Minocycline concen-
trations of 50 µM (P , 0.001) and higher for primary ONHA 
led to a dose-dependent reduction of viability. When ONHA 
cells were treated additionally with H2O2, cells pretreated 
with minocycline concentrations .15 µM (P = 0.02) up to 
50 µM (P = 0.01) showed a significantly increased viability 
with a peak at 20 µM (P , 0.001) compared with the control. 
Only concentrations as high as 150 µM showed significantly 
decreased viability (P , 0.001, Figure 2).
Minocycline concentrations of 50 µM (P = 0.005) and 
higher for primary TMC led to a dose-dependent reduc-
tion of viability (Figure 3). When TMC cells were treated 
additionally with H2O2, the cells pretreated with minocy-
cline concentrations of .7.5 µM (P , 0.001) up to 50 µM 
(P = 0.002) showed significantly increased viability, with 
a peak at 40 µM (P , 0.001) compared with the control. 
Concentrations of 75 µM (P = 0.01) and higher showed 
significantly decreased viability (Figure 3). Minocycline 
concentrations of 100 µM and 150 µM for primary TMC and 
150 µM for ONHA markedly reduced the proliferation rate 
to less than 20%. ONHA and TMC treated with minocycline 
and TGFβ-2 showed similar results to those of ONHA and 
TMC treated with minocycline only (data not shown).
Viability assay
The viability of primary ONHA was tested by labeling the 
nuclei of nonviable cells with propidium iodide 48 hours after 
treatment of the cells. For ONHA, minocycline concentrations 
1–75 µM did not show any significant effect on cell viability 
(data not shown). If primary ONHA were treated with mino-
cycline concentrations for 48 hours and additionally treated 
with 600 µM H2O2 for four hours, minocycline concentrations 
of 20 µM (P , 0.001) led to a significant increase in viability 
compared with the control treated with 600 µM H2O2 only 
(Figure 4N). By contrast, minocycline concentrations of 75 µM 
and higher induced a marked reduction of viable ONHA cells 
in a dose-dependent manner (Figure 4A–N). TMC (Figure 4O) 
showed results similar to those of primary ONHA cells.
expression of Bcl-2, XiAP, and survivin 
mrnA in OnhA and TMC
ONHA and TMC from four donors were used to investigate 
mRNA expression of Bcl-2, XIAP, and survivin. Bcl-2, 
TMC cells
AB
CD
EF
Control
M 20 µM
M 40 µM
LM
IK
GH
ONHA cells
Figure 1 Phase-contrast microscopy of primary TMC (A–F) and OnhA cells (G–M). After treatment with minocycline 20 µM and 40 µM for both cell lines (TMC: C, e; 
OnhA: i, L), no morphologic changes could be detected. When cells were treated additionally with 600 µM h2O2, neither TMC nor OnhA pretreated with minocycline   
20 µM and 40 µM (TMC: D, F; ONHA: K, M) showed any significant morphologic changes. In contrast, cells that were only treated with 600 µM H2O2 showed marked signs 
of destruction and cell death (TMC: B; OnhA: h). scale (10×)
Abbreviations: TMC, trabecular meshwork cells; OnhA; optic nerve head astrocytes.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 2 Viability of primary OnhA cells after treatment with the investigated concentrations of minocycline (black curve, diamond) and additionally treated with 600 µM 
h2O2 (grey curve, triangles), measured by a colorimetric test (MTT). Tests were performed in triplicate and repeated three times. Untreated primary OnhA of the same 
passage served as the control. results are expressed as the mean percentage of control cell survival. The data are the mean of results of three experiments, each performed 
in triplicate. Cells treated only with minocycline concentrations up to 40 µM showed no reduction in viability compared with the control, while 50 µM and higher showed 
a significantly reduced viability (P , 0.001). When cells were treated additionally with h2O2, those pretreated with minocycline .15 µM (P = 0.02) up to 50 µM (P = 0.01) 
showed a significantly increased viability, with a peak at 20 µM (P , 0.001) compared with the control. Only concentrations as high as 150 µM showed significantly decreased 
viability (P , 0.001). error bars, ± sD.
Abbreviations: OnhA; optic nerve head astrocytes; sD, standard deviation.
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Figure 3 Viability of primary TMC after treatment with the investigated concentrations of minocycline (black curve, squares) and additionally treated with 600 µM h2O2 
(grey curve, triangles), measured by MTT assay. TMC treated only with minocycline concentrations up to 40 µM showed no reduction in viability compared with the control. 
Minocycline 50 µM (P = 0.005) and higher for primary TMC led to a dose-dependent reduction of viability. When TMC cells were treated additionally with h2O2, those 
pretreated with minocycline .7.5 µM (P , 0.001) up to 50 µM (P = 0.002) showed significantly increased viability, with a peak at 40 µM (P , 0.001) compared with the 
control. Concentrations of 75 µM (P = 0.01) and higher showed a significantly decreased viability. Error bars, ± sD.
Abbreviations: TMC, trabecular meshwork cells; sD, standard deviation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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XIAP, and survivin mRNA expression were detectable in 
every sample. All detected mRNA levels of Bcl-2, XIAP, 
and survivin were normalized to those of 18S rRNA, and 
the values are expressed as the relative ratio of Bcl-2/18S, 
XIAP/18S, or survivin/18S.
Our findings indicate that treatment with minocycline 
leads to increased mRNA expression for both investigated 
cell lines for all three tested antiapoptotic proteins. In contrast, 
TGFβ-2 and H2O2 treatment decreased mRNA expression of 
Bcl-2, XIAP, and survivin in both ONHA and TMC (Figures 
5, 6, and 7). Cells treated with minocycline and with TGFβ-2 
or H2O2 seemed to compensate for the detected decrease of 
Bcl-2, XIAP, and survivin mRNA expression. Minocycline-
treated cells reached mRNA levels of Bcl-2, XIAP, and 
survivin comparable with those of the untreated control, or 
even higher. In addition, cells pretreated with minocycline 
and then treated with TGFβ-2 or H2O2 showed significantly 
higher levels of Bcl-2, XIAP, and survivin mRNA in ONHA 
and TMC than cells treated only with TGFβ-2 or H2O2. These 
effects were found for both ONHA and TMC when cells 
were treated with minocycline concentrations of 20 µM and 
40 µM (Figures 5, 6, and 7). When cells were treated with 
minocycline concentrations less than 10 µM, the described 
effects decreased and did not reach statistical significance 
(data not shown).
Protein expression of Bcl-2, XiAP, and 
survivin in OnhA and TMC
To verify that the increase in mRNA transcription of 
Bcl-2, XIAP, and survivin by minocycline translates into 
increased protein synthesis, whole cellular protein extracts 
of untreated control cells, cells treated with minocycline 
alone, and cells treated with minocycline and then with 
TGFβ-2 or 600 µM H2O2, were analyzed by Western blot-
ting. When cells were treated with 600 µM H2O2, Bcl-2 
expression decreased 10-fold in ONHA and twofold in 
Hoechst 33342
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Figure 4 Primary OnhA and TMC were treated for 48 hours with various concentrations of minocycline only or additionally treated with 600 µM h2O2 for four hours. 
After exposure of the cells to the substance alone and in combination with oxidative stress, viability was determined by staining all nuclei with hoechst 33342 and dead cells 
with propidium iodide. (A) Representative fluorescence photomicrograph of Hoechst 33342-stained, untreated ONHA as control. (B) nonviable cells in the corresponding 
field. Fluorescence photomicrograph of ONHA treated with minocycline 20 µM (C) and 40 µM (E) for 48 hours and labeled with hoechst 33342. nonviable OnhA treated 
with minocycline 20 µM (D) and 40 µM (F) for 48 hours in the same field as in (C) and (E). Fluorescence photomicrograph of OnhA treated with 600 µM h2O2 only (G) 
and with minocycline 20 µM (I) and 40 µM (L) for 48 hours and additionally treated with 600 µM h2O2 and labelled with hoechst 33342. nonviable OnhA treated with 
600 µM h2O2 only (H) and with minocycline 20 µM (K) and 40 µM (M) for 48 hours and additionally treated with 600 µM h2O2 in the same field as in (G, I, L). TMC yielded 
a similar result (data not shown). Quantification of effect of minocycline treatment alone and additional treatment with H2O2 on numbers of nonviable primary OnhA (N) 
and TMC (O). The percentage of dead cells was scored by counting at least 500 cells in fluorescence photomicrographs of representative fields. Data (mean ± sD) are based 
on the sampling of 6–10 photomicrographs per condition in three independent experiments performed in duplicate. Comparison with controls is shown above the bars with 
significant differences marked by an asterisk.
Abbreviations: TMC, trabecular meshwork cells; OnhA; optic nerve head astrocytes; sD, standard deviation.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 5 Bcl-2 mrnA expression of OnhA and TMC after treatment with minocycline 20 µM and 40 µM only or after additional treatment with 600 mM h2O2 or TgFβ-2, 
as investigated by quantitative rT-PCr. All tests were performed in triplicate and repeated three times. The mrnA levels were normalized to those of 18s rrnA and 
expressed as the ratio of Bcl-2 mRNA/18S rRNA. ONHA treated with minocycline concentrations showed a significant increase in Bcl-2 mRNA expression compared with 
the control in both cell lines. TgFβ-2 and h2O2 treatment decreased Bcl-2 expression. When OnhA cells were treated with minocycline 20 µM and 40 µM and TgFβ-2 
or h2O2, Bcl-2 expression was increased compared with OnhA treated only with TgFβ-2 or h2O2. similarly, TMC treated with minocycline 20 µM and TgFβ-2 or h2O2 
showed an increased expression of Bcl-2 mrnA compared with TMC treated only with TgFβ-2 or h2O2. All differences between the two minocycline concentrations and 
the corresponding controls are statistically significant.
Key: x-axis, rr of Bcl-2 mrnA normalized to 18s rrnA expressed in decimal format; y-axis, tested concentrations of minocycline.
Abbreviations: TMC, trabecular meshwork cells; OnhA; optic nerve head astrocytes; rT-PCr, real time polymerase chain reaction; rr, relative ratio; TgFβ-2, transforming 
growth factor-beta-2.
TMC compared with the control (Figure 8). TGFβ-2 
treatment (1 ng/mL) decreased Bcl-2 expression by 
approximately 2.5-fold in ONHA and by twofold in TMC. 
Treatment with minocycline alone did not increase protein 
expression of Bcl-2 or XIAP in primary human ONHA or 
TMC. Compared with cells treated only with H2O2, cells 
pretreated with 20 µM minocycline and then with H2O2 
showed a significantly lower decrease of Bcl-2 of approxi-
mately 1.5-fold in ONHA cells and a 1.25-fold increase 
in TMC and a significant increase of 7.5-fold in ONHA Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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cells and twofold in TMC. When cells were treated with 20 
µM minocycline and TGFβ-2, Bcl-2 expression increased 
by approximately twofold in ONHA cells and by 1.5-fold 
in TMC cells, compared with cells treated with TGFβ-2 
only. The decrease of Bcl-2 compared with the untreated 
control was 1.5-fold in ONHA cells and two-fold in TMC 
cells, which was significantly lower than the decrease after 
TGFβ-2 treatment only (Figure 8).
The XIAP expression decreased 2.5-fold in ONHA 
cells and fivefold in TMC cells treated with 600 µM H2O2 
ONHA: RNA expression of XIAP
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Co M 20 M 40 M 20 + 
Tgf-ß2 
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Figure 6 XiAP mrnA expression of OnhA and TMC after treatment with minocycline only and after additional treatment with h2O2 or TgFβ-2. OnhA treated with 
40 minocycline µM showed a significant increase in XIAP mRNA expression compared with the control in both cell lines. TGFβ-2 and h2O2 treatment slightly decreased 
XiAP expression in OnhA and treatment with minocycline 20 µM and 40 µM and TgFβ-2 or h2O2 increased expression of XiAP compared with OnhA treated only with 
TgFβ-2 or h2O2. TMC treated with minocyline 20 µM and TgFβ-2 or h2O2 showed an increased expression of XiAP mrnA compared with TMC treated only with TgFβ-2 
or h2O2. All differences between the two minocycline concentrations and the corresponding controls are statistically significant.
Key: x-axis, rr of XiAP mrnA normalized to 18s rrnA expressed in decimal format; y-axis, tested concentrations of minocycline.
Abbreviations: TMC, trabecular meshwork cells; OnhA; optic nerve head astrocytes; rr, relative ratio; TgFβ-2, transforming growth factor-beta-2.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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(Figure 9). TGFβ-2 decreased XIAP expression 10-fold 
in ONHA cells and twofold in TMC cells, compared with 
the control. Cells pretreated with 20 µM minocycline and 
then with H2O2 showed a significantly lower decrease of 
XIAP expression of 1.5-fold in ONHA cells and 1.25-fold 
in TMC cells than those cells that were treated with H2O2 
only (2.5×) (TMC 5×). The same effect could be detected 
for TGFβ-2 treatment, whereby ONHA and TMC cells pre-
treated with minocycline 20 µM showed no decrease in XIAP 
expression compared with the control, but cells treated with 
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Figure 7 survivin mrnA expression measured by quantitative rT-PCr. OnhA treated with minocycline 40 µM showed a significant increase in survivin mRNA expression 
compared with the control. TMC showed this increase for minocycline 20 µM and 40 µM. TgFβ-2 decreased survivin expression, and h2O2 treatment slightly decreased 
survivin expression for both cell lines. Treatment with minocycline 20 µM and 40 µM and additional treatment with TgFβ-2 increased expression of survivin compared with 
cells treated only with TgFβ-2. For cells treated additionally with h2O2, OnhA cells only showed a slight increase and TMC cells showed a more pronounced increase when 
pretreated with minocycline concentrations compared with cells treated with h2O2 only. All differences between the two minocycline concentrations and the corresponding 
controls are statistically significant except for the H2O2 group with OnhA.
Abbreviations: TMC, trabecular meshwork cells; OnhA; optic nerve head astrocytes; rT-PCr, real time polymerase chain reaction; TgFβ-2, transforming growth   
factor-beta-2.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Figure 9 expression of XiAP. Western blot showing the protein expression of XiAP 
in control (Co) and treated cell extracts: TgFβ-2 (Tgf), minocycline 20 µM (M20), 
minocycline 20 µM and TgFβ-2 (M20+Tgf), 600 µM h2O2 (h2O2), and treatment 
with minocycline 20 µM and 600 µM h2O2 (M20 + h 2O2). Ten micrograms of 
protein were loaded per lane.
Abbreviations:  TMC,  trabecular  meshwork  cells;  OnhA;  optic  nerve  head 
astrocytes; TgFβ-2, transforming growth factor-beta-2.
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+
Tgf
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+
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Expression of Bcl-2
Figure 8 effect of minocycline treatment on Bcl-2 protein expression. OnhA 
and TMC were treated with minocycline 20 µM only or additionally with TgFβ-2   
(1 ng/mL) or 600 µM h2O2. Western blotting was used to analyze protein expression 
in control (Co) and treated cell extracts: TgFβ-2 (Tgf), 20 µM minocycline (M20), 
minocycline 20 µM and TgFβ-2 (M20+Tgf), 600 µM h2O2 (h2O2), and minocycline 
20 µM and 600 µM h2O2 (M20 + h2O2). Ten micrograms of protein was loaded 
per lane.
Abbreviations:  TMC,  trabecular  meshwork  cells;  OnhA;  optic  nerve  head 
astrocytes; TgFβ-2, transforming growth factor-beta-2.
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Figure 10 expression of survivin. Western blot showing the protein expression 
of survivin in control (Co) and treated cell extracts: TgFβ-2 (Tgf), minocycline 
20 µM (M20), minocycline 20 µM and TgFβ-2 (M20+Tgf), 600 µM h2O2 (h2O2), 
and minocycline 20 µM and 600 µM h2O2 (M20 + h2O2). Ten micrograms of protein 
were loaded per lane.
Abbreviations:  TMC,  trabecular  meshwork  cells;  OnhA;  optic  nerve  head 
astrocytes; TgFβ-2, transforming growth factor-beta-2.
TGFβ-2 only did show a 10-fold decrease in XIAP   expression 
in ONHA cells and a twofold decrease in expression in TMC 
cells (Figure 9).
Survivin expression in ONHA decreased fivefold 
in ONHA cells and 2.5-fold in TMC cells treated with 
600 µM H2O2 (Figure 10). TGFβ-2 decreased XIAP 
expression by 2.5-fold in ONHA cells and by twofold 
in TMC compared with the control. When ONHA cells 
were treated with minocycline 20 µM, a 2.5-fold increase 
in survivin expression was detected in ONHA cells but 
not for TMC cells. ONHA cells pretreated with minocy-
cline 20 µM and then with H2O2 600 µM showed a slight 
increase of survivin expression of 1.1-fold in ONHA cells, 
while TMC cells showed a decrease of twofold compared 
with the control. By contrast, cells treated only with 
H2O2 showed a fivefold decrease in survivin expression 
in ONHA cells and a 2.5-fold decrease in TMC cells. 
ONHA cells pretreated with minocycline 20 µM and 
then treated with TGFβ-2 showed a 1.5-fold increase in 
survivin expression compared with the control, which was 
a 3.5-fold higher survivin expression compared with cells 
treated with TGFβ-2 only. TMC cells pretreated with 
minocycline 20 µM showed a lower decrease of survivin 
expression of 1.25-fold than cells treated with TGFβ-2 
only (twofold, see Figure 10).
Discussion
Glaucomatous loss of visual field is mainly due to RGC 
death and neuronal degeneration, and there is evidence 
that these cells mainly die as a result of apoptosis.19–22 IOP 
elevation and visual field damage have been shown to be 
proportional to oxidative damage in the human TM.16 Cell 
loss, altered functionality, and a decrease in the outflow facil-
ity of the TM have been suggested as a result of oxidative 
damage in the TM.47,48 In addition, a significantly decreased 
TM cellularity, especially in the filtering area of the TM, is 
found in patients suffering from glaucoma, compared with 
age-matched nonglaucomatous subjects.9 Recent data sug-
gest that these structural changes in the TM and a decrease 
in TMC, which leads to elevated IOP, are also triggered by 
apoptosis,10,23,24 so antiapoptotic and neuroprotective agents 
could support and complement the proven but incomplete 
therapeutic effect of decreasing IOP. Our findings demon-
strate that minocycline effectively protects primary human 
TMC and ONHA in vitro against oxidative stress and induces 
a marked reduction in cellular death. We were able to show 
that this protection is associated with the induction of three 
antiapoptotic proteins, ie, Bcl-2, XIAP, and survivin. These 
three proteins are known inhibitors of major pathways of 
apoptosis.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Apoptosis is a mechanism that is genetically controlled by 
the dying cell, resulting in the activation of tumor suppressor 
proteins49 and apoptosis-initiating caspases.50 One mechanism 
in the cell death program is upregulation of the proapoptotic 
Bax protein. This increase in Bax expression effects a change 
in the permeability of mitochondrial membranes. That leads 
to the release of cytochrome c and the activation of caspases, 
which finally proteolyze cellular components.51 Bcl-2 is one 
of the key genes known to downregulate Bax and p53, and 
therefore has the potency to inhibit this apoptotic pathway.52,53 
Therefore, pharmacologic upregulation of Bcl-2 is a highly 
interesting approach to inhibition of apoptosis.
XIAP and survivin are members of a group of proteins 
called inhibitors of apoptosis (IAPs).54–56 XIAP inhibits 
apoptosis by directly blocking the activity of the terminal 
effector cell death proteases, caspases 3, 7, and 9. It has been 
demonstrated in vivo that overexpression of XIAP protects 
injured neuronal cells and photoreceptors from further com-
promise.57,58 Survivin interacts with p2159 and thus suppresses 
Fas-mediated cell death.60 Its antiapoptotic effects seem to 
result from its ability to block caspases 3 and 7. In addi-
tion, survivin prevents cells from responding to apoptotic 
stimuli.61 Bcl-2, XIAP, and survivin, all show antiapoptotic 
effects. Because minocycline upregulates RNA levels of 
Bcl-2, XIAP, and survivin in ONHA and TMC, it has high 
antiapoptotic potency on those cell lines.
There is evidence that both oxidative stress and elevated 
levels of TGFβ-2 support the development and progression 
of glaucoma.16–18,62,63 For this reason, the present study inves-
tigated TGFβ-2, the isoform of TGFβ that is expressed most 
in human eyes. Recent studies have shown that elevated levels 
of TGFβ, especially TGFβ-2, are found in glaucomatous eyes 
and seem to have a major influence on the pathogenesis of 
glaucoma.17,18 So another important finding of our study is 
that TGFβ-2 downregulates both mRNA levels and protein 
expression of Bcl-2, XIAP, and survivin in primary human 
ONHA and TMC. In contrast, minocycline protects both cell 
lines against TGFβ-2-induced downregulation of these three 
antiapoptotic proteins and returns levels back to normal or 
even increases them. We were also able to show that minocy-
cline protects ONHA and TMC against oxidative stress, which 
is another important pathologic trigger for glaucoma.
Because of its antibiotic and anti-inflammatory actions, 
minocycline is widely used, and has had proven safety as 
an oral antibiotic for many years.27,28 Because minocycline 
crosses the blood–brain barrier effectively25 and penetrates 
well into the eye,26 the optic nerve and ocular cells are poten-
tially   susceptible to oral treatment. Due to the very good 
bioavaila  bility of minocycline, the tested concentration of 
20 µM would correspond to an estimated dose of approxi-
mately 750 mg/day in adult humans, which is undoubtedly a 
high dosage. On the other hand, previous reports have shown 
that daily tetracycline doses even higher than 2000 mg are still 
relatively safe in healthy pregnant women.27 Therefore, it might 
be worthwhile to investigate the antiapoptotic and cytoprotec-
tive effects of minocycline in glaucoma treatment further.
Glaucoma is a chronic disease, and the long-term 
  utilization of antibiotics is known to be associated with side 
effects.64,65 Minocycline seems to be safe even for long-term 
high-dose treatment66 but, in the end, the relatively high dos-
ages needed to achieve the cytoprotective effects described 
here might limit its application as long term medication. On 
the other hand, there are situations where acute cell stress is 
predominant, ie, in cases of acute glaucoma or in end-stage 
glaucoma patients needing glaucoma-filtering surgery, 
where the risk of “wipeout” (loss of the central visual field) 
is feared.67,68 In such cases, minocycline might offer a new 
option to protect affected eyes from further damage.
Our results demonstrate the cytoprotective effects of 
minocycline on primary human ONHA and TMC. These 
in vitro data cannot be automatically extrapolated to an in vivo 
situation. Even high doses of minocycline are tolerated well 
in vivo27,66 but it is not clear if this cytoprotective action of 
minocycline is effective in the long term and whether it is 
actually possible to reach therapeutic concentrations inside 
the eye. Further investigations are therefore needed on 
these points. Certainly further basic and clinical studies are 
needed, but the present study makes an early contribution 
towards shedding light on the potential protective effects of 
minocycline and to find possible new treatment strategies 
for glaucoma.
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